focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.30
Ask: 4.50
Change: 0.29 (8.26%)
Spread: 1.20 (36.364%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 pushes higher ahead of Fed chair speech

Fri, 25th Aug 2023 12:07

(Alliance News) - The FTSE 100 edged higher at midday on Friday as all eyes turned to US Federal Reserve Chair Jerome Powell's address at Jackson Hole later in the day.

The FTSE 100 index was up 35.67 points, or 0.5%, at 7,369.51. Meanwhile, the FTSE 250 was up just 3.12 points at 18,197.69, and the AIM All-Share was virtually flat at 734.50.

The Cboe UK 100 was up 0.4% at 734.13, the Cboe UK 250 was down 0.1% at 15,921.01, and the Cboe Small Companies was up 0.3% at 12,842.82.

Jerome Powell is due to give a 25-minute speech at around 1005 EDT, or 1505 BST.

According to analysts at Lloyds Bank, investors will be looking for two key points in his remarks. Firstly, any sign of Powell confirming a pause to interest rate hikes at the next meeting in September. Secondly, whether he will indicate that rates are likely to have peaked and when they could be cut.

Francesco Pesole at ING remarked that some Fed speakers have already laid the groundwork for Friday's keynote speech, with Patrick Harker, president of the Federal Reserve Bank of Philadelphia, leaning on the dovish side and saying that the Fed has "probably done enough" on policy tightening.

Pesole noted that Susan Collins, president of the Federal Reserve Bank of Boston, also suggested the Fed may have to hold for some time, though she refrained from signalling where the peak is.

There will also be an address from European Central Bank President Christine Lagarde later on Friday.

During the Saturday session, there will be a panel featuring Bank of England Deputy Governor Ben Broadbent and Bank of Japan Governor Kazuo Ueda, which will discuss the topic of 'Globalization at an Inflection Point'.

The dollar was firmly on the front foot midday on Friday as traders readied themselves for Powell's address.

The pound was quoted at USD1.2595 at midday on Friday in London, down from USD1.2639 at the equities close on Thursday. The euro stood at USD1.0797, lower against USD1.0835. Against the yen, the dollar was trading at JPY146.03, higher compared to JPY145.66.

In London, Watches of Switzerland plunged 21% despite reassuring the market that the acquisition by Rolex of Swiss watch retailer Bucherer will not change its relationship with the key supplier.

"Investors seem to fear the tie-up will mean Bucherer gets preferential treatment including better access to the watches that consumers are desperate to buy," Russ Mould, investment director at AJ Bell explained.

Rolex on Thursday announced it will buy Bucherer to "preserve the close partnership ties that have linked both companies since 1924".

Watches of Switzerland said the acquisition doesn't represent a strategic move into retail by Rolex, and there will be no change in the product allocation or distribution of Rolex watches.

Watches of Switzerland said it had this "confirmed by the highest level of Rolex management" in Geneva.

Analysts at Shore Capital said that while the news marked a "significant shift" in the luxury watch market, it is not revising its estimates at this stage as it believes that the deal is "unlikely" to impact Watches of Switzerland's sales of Rolex in the short term.

Shore added it would be "keenly observing" the market's response to the news on Friday, saying if there were to be a "substantial drop in value" there may be an "attractive buying opportunity" for the stock.

Aston Martin was the best performer in the FTSE 250, up 5.7%, after Jefferies raised the luxury car maker to 'buy' from 'hold'.

"Current metrics look worse or no better than at the 2018 [initial public offering]. However, now feels like a new start at [Aston Martin] with net debt stabilized, renewed focus on front-engine cars and sharp [average selling price] upgrades," Jefferies explained.

CMC Markets slid 15% after the online trading platform warned of a drop in annual income as "subdued market conditions" in the month of August weighed on trading.

CMC now expects net operating income of between GBP250 million and GBP280 million for financial 2024, falling short of GBP288.4 million in financial 2023.

This was attributed to "markedly lower monetisation of client trading activity due to a higher proportion of lower margin institutional volume".

On AIM, Proteome Sciences fell 21% after it reported it swung to a loss in the first half of 2023, amid higher costs and virtually flat revenue.

The protein-focused drug development services provider said its pretax loss in the first half of the year was GBP547,000, swung from a profit of GBP75,000 a year prior. Revenue remained largely flat at GBP3.2 million.

Administrative expenses increased 26% to GBP1.9 million from GBP1.5 million, and finance costs doubled to GBP384,000 from GBP192,000.

Looking ahead, Chief Executive Officer Mariola Soehngen said: "The board is confident of maintaining the good performance into the second half of the year. Tandem Mass Tags revenues remain strong and we have a good dynamic in the order generation of our service business. The launch of SysQuant SCP and the setting up of our US lab are important investments and we expect these to provide a good basis for further growth of the business."

In European equities on Friday, the CAC 40 in Paris was up 0.7%, while the DAX 40 in Frankfurt was up 0.5%.

Stocks in New York were called higher. The Dow Jones Industrial Average was called up 0.3%, the S&P 500 index up 0.3%, and the Nasdaq Composite up 0.1%.

Brent oil was quoted at USD83.79 a barrel at midday in London on Friday, up from USD82.41 late Thursday. Gold was quoted at USD1,917.50 an ounce, lower against USD1,921.41.

By Heather Rydings, Alliance News senior economics reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
18 Sep 2013 15:03

Proteome Expects Strong Second-Half Growth After Making Alzheimer's Progress

Read more
12 Jun 2013 11:37

Proteome Sciences to develop cancer pathway profiling assays

AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov

Read more
18 Mar 2013 14:29

Proteome Sciences looks ahead with confidence

Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha

Read more
31 Dec 2012 12:50

STOCKS NEWS EUROPE-UK small caps closes modestly higher

The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv

Read more
31 Dec 2012 10:48

Proteome delivers encouraging results from Alzheimers study

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin

Read more
28 Sep 2012 10:46

Proteome Sciences narrows losses, bright outlook

Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services

Read more
18 Sep 2012 10:57

Proteome stroke test could save thousands from brain damage

Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall

Read more
20 Aug 2012 07:43

London pre-open: Doubts about further Chinese stimulus

City sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European

Read more
20 Aug 2012 07:20

Proteome Sciences reports collaboration research agreement

Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility

Read more
5 Apr 2012 11:50

Proteome issues new licence for stroke product

Pharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear

Read more
28 Mar 2012 10:46

Proteome rockets on Alzheimer's blood test

Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive

Read more
19 Mar 2012 10:17

Stroke consortium to get €11m grant

Shares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f

Read more
27 May 2011 12:09

Proteome boosted by Sanofi settlement

Biomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010

Read more
30 Nov 2010 13:34

Small caps round-up: Tinci, Nasstar, 600 Group...

Environmental engineering group Tinci Holdings jumped after it announced contracts worth 45.4m Chinese Renminbi (£4.34m) to provide paper desulfurisation technology to two subsidiaries of the Dongguan Jiulong Paper Group. These projects are expected to start shortly and last for about six months. N

Read more
13 Jul 2010 09:30

UK SMALLCAP ROUNDUP: African Minerals Gets $1.5B For Tonkolili

Dow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps AFRICAN MINERALS LTD. (AMI.LN), an iron ore miner focused on Sierra Leone, Tuesday said it agreed a $1.5 billion investment in its Tonkolili project from

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.